SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

PCA Dealing

3 Mar 2026 16:04

RNS Number : 1836V
Tristel PLC
03 March 2026

Tristel plc

("Tristel" or the "Company")

PCA Dealing

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it was notified on 3 March 2026 that Glenn Stephens, a PCA of Caroline Stephens, Non-Executive Director of the Company, purchased 2,310 ordinary shares of 1 penny each in the Company ("Ordinary Shares") at a price of 389 pence per Ordinary Share.

Following the purchase, Caroline Stephens' beneficial interest in the Company, including those held by her PCA, is 4,281 Ordinary Shares, representing approximately 0.01 per cent. of the Company's issued share capital.

For further information please contact:

Tristel plc

Via Walbrook PR

Matt Sassone, Chief Executive Officer

www.investors.tristel.com

Anna Wasyl, Chief Financial Officer

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus / Lianne Applegarth / Anna Dunphy

Mob: 07980 541 893/ 07584 391 303/ 07876 741 001

Cavendish Capital Markets Ltd

Tel: 020 7220 0500

Geoff Nash / Callum Davidson / Joe Smith (Corporate Finance)

Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals with products under the Tristel brand, which also encompasses its sporicidal surface disinfection range offered as a sustainable alternative to commonly used pre?wetted plastic wipe.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets delivering double-digit revenue growth annually, an adjusted EBITDA margin of at least 25% and a continuing progressive year-on-year growth in dividends, underpinned by robust cash generation.

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: https://tristel.com

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Glenn Stephens

2

Reason for the notification

a)

Position/status

PCA of Caroline Stephens, Non-Executive Director of the Company

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Tristel plc

b)

LEI

2138009DZ4LH9CZGF662

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 1p each in Tristel plc

GB00B07RVT99

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price

Volume

389 pence

1,540

389 pence

770

d)

Aggregated information

- Aggregated volume

- Price

2,310 Ordinary Shares of 1 penny each

389 pence

e)

Date of the transaction

3 March 2026

f)

Place of the transaction

London Stock Exchange (AIM)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHAKNBKABKDKNK
Date   Source Headline
27th Oct 20204:50 pmRNSIssue of Equity
19th Oct 20203:15 pmRNSDividend Timetable
19th Oct 20207:00 amRNSFinal Results
6th Oct 20207:00 amRNSNotice of Results
5th Oct 20204:41 pmRNSIssue of Equity
2nd Oct 20209:11 amRNSIssue of Equity
7th Sep 20201:16 pmRNSIssue of Equity
21st Aug 20207:00 amRNSTristel’s Duo for Ultrasound approved in India
7th Aug 202010:46 amRNSIssue of Equity
6th Aug 202010:30 amRNSUpdate from Virtual Shareholder Open Day
22nd Jul 20204:43 pmRNSDirector/PDMR Shareholding and Issue of Equity
22nd Jul 20209:05 amRNSSecond Price Monitoring Extn
22nd Jul 20209:00 amRNSPrice Monitoring Extension
22nd Jul 20207:00 amRNSTrading update
23rd Jun 20207:00 amRNSNotice of Trading update, Results & presentation
8th Jun 202010:40 amRNSIssue of Equity
22nd May 20209:47 amRNSIssue of Equity
28th Apr 20203:40 pmRNSIssue of Equity
27th Apr 20207:00 amRNSDirector Appointment
14th Apr 202010:02 amRNSIssue of Equity
7th Apr 202010:38 amRNSIssue of Equity
31st Mar 20208:00 amRNSHolding(s) in Company
25th Mar 202012:38 pmRNSHolding(s) in Company
23rd Mar 20209:05 amRNSSecond Price Monitoring Extn
23rd Mar 20209:00 amRNSPrice Monitoring Extension
23rd Mar 20207:00 amRNSLicense & Product Supply Agreement with Byotrol
20th Mar 20204:43 pmRNSSecond Price Monitoring Extn
20th Mar 20204:40 pmRNSPrice Monitoring Extension
17th Mar 20204:42 pmRNSSecond Price Monitoring Extn
17th Mar 20204:37 pmRNSPrice Monitoring Extension
13th Mar 20204:14 pmRNSIssue of Equity
10th Mar 202011:56 amRNSIssue of Equity
6th Mar 20201:42 pmRNSHolding(s) in Company
3rd Mar 202010:24 amRNSDirector/PDMR Shareholding and Issue of Equity
26th Feb 20207:00 amRNSHolding(s) in Company
25th Feb 20209:06 amRNSDirector/PDMR Shareholding (Replacement)
25th Feb 20207:00 amRNSDirector/PDMR Shareholding
24th Feb 20207:00 amRNSHalf-year Report
20th Feb 202011:12 amRNSIssue of Equity
18th Feb 20209:51 amRNSIssue of Equity
30th Jan 20203:43 pmRNSIssue of Equity
15th Jan 20207:00 amRNSInvestor results presentation
14th Jan 20201:09 pmRNSIssue of Equity
17th Dec 201911:01 amRNSResult of AGM
17th Dec 20197:00 amRNSAGM Statement and notice of results
4th Dec 20199:30 amRNSIssue of Equity
3rd Dec 201911:20 amRNSHolding(s) in Company
26th Nov 20197:00 amRNSForthcoming Appointment of Non-Executive Chairman
20th Nov 201910:08 amRNSIssue of Equity
18th Nov 20197:00 amRNSUpdate on MobileODT strategic investment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.